On June 22, 2026, the Food and Drug Administration issued a revised draft guidance titled Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, with a formal notice of availability published in the Federal Register on June 24, 2026 (docket FDA-2026, document 2026-12622). The document revises a draft of the same title FDA first issued in December 2019, which was never finalized. For sponsors, CROs, and academic medical centers running or planning registrational trials, this is the agency’s clearest statement yet on when a single adequate and well-controlled study can carry an approval on its own.
What the revised draft guidance covers
The Federal Food, Drug, and Cosmetic Act’s substantial-evidence-of-effectiveness standard (section 505(d)) has historically been read, in practice, as requiring two independent adequate and well-controlled trials before FDA will approve a new drug or biological product. That reading was never an absolute statutory requirement — the statute itself allows for reliance on “one adequate and well-controlled clinical investigation and confirmatory evidence” — but it became the default expectation sponsors planned around.
The 2026 revised draft guidance reframes that default. It walks through the factors FDA says can strengthen or weaken the evidentiary contribution of a single trial — effect size, biological plausibility, mechanism of action, replication of a related effect in a different population, and the quality and independence of confirmatory data — and describes a broader set of circumstances in which one adequate and well-controlled trial plus confirmatory evidence (which can include real-world evidence, pharmacokinetic/pharmacodynamic data, or evidence from a related indication) may satisfy section 505(d) without a second dedicated pivotal study.
FDA frames the revision as a response to public comment on the 2019 draft and to changes in how evidence is generated and evaluated since then, including growth in high-quality real-world and biomarker data. The guidance does not eliminate the two-trial paradigm — it remains the default FDA describes for most drug development programs — but it narrows the circumstances treated as exceptional.
Why this matters for research administrators and clinical trial teams
A shift toward single-pivotal-trial pathways changes the planning calculus well before an IND is filed. Sponsors weighing a single confirmatory-evidence-supported trial against a conventional two-trial program need to build that evidentiary case into protocol design, statistical analysis plans, and pre-IND meeting briefing packages from the outset, since FDA’s guidance makes clear the strength of confirmatory evidence is assessed holistically rather than checked off a fixed list.
The guidance sits alongside — and in the same evidentiary vocabulary as — FDA’s existing expedited pathways (Breakthrough Therapy, Accelerated Approval) and its growing use of validated surrogate endpoints and adaptive trial designs. Sponsors already using those tools should expect FDA reviewers to apply the same evidentiary-strength reasoning described in this guidance when weighing whether a single trial from an adaptive or seamless design is sufficient. A sponsor that misjudges how much confirmatory evidence a reviewing division will require risks a Complete Response Letter rather than approval.
Comment period and what happens next
This is draft, non-binding guidance — it represents FDA’s current thinking, not a new regulation, and sponsors may propose an alternative approach that satisfies the underlying statute and 21 CFR 314.126. FDA is accepting electronic and written comments on the revised draft through September 22, 2026, before beginning work on a final version. Given that the 2019 draft on the same topic was never finalized, research administrators should treat the current document as directional rather than settled: it signals where FDA’s thinking is headed, but the two-trial default remains the operative expectation for most programs until a final guidance issues.
Frequently asked questions
Does this guidance change what FDA requires today?
Not immediately. It is a revised draft, not a final guidance, and draft guidances are explicitly non-binding. It signals how FDA reviewers are currently thinking about single-trial evidence packages, which is useful for planning, but it does not change 21 CFR 314.126 or FDA’s current review practice on its own.
What is “confirmatory evidence” in this context?
FDA uses the term broadly: it can include evidence from a related population or indication, pharmacokinetic or pharmacodynamic data, mechanistic or biomarker data, and real-world evidence, among other sources — anything that corroborates the effect shown in the single adequate and well-controlled trial without itself being a second independent pivotal study.
How does this differ from the 2019 draft guidance on the same topic?
Both drafts address the same statutory question — when one trial plus confirmatory evidence satisfies section 505(d) — but FDA describes the 2026 revision as responding to public comments on the 2019 draft and to since-2019 changes in evidence generation, including greater availability of high-quality real-world and biomarker data. The 2019 draft was never finalized, so the 2026 document supersedes it as the current draft framework.
Who should be tracking this guidance?
Regulatory affairs, biostatistics, and clinical development teams planning pivotal-trial strategy for an NDA or BLA are the primary audience, but research administrators supporting investigator-initiated registrational work and academic medical centers with translational drug-development programs should also watch how the final guidance lands, since it affects what evidentiary package a sponsor needs before FDA will consider a program approval-ready.
